Clinical trials: Myelosuppression
Non-Small Cell Lung Cancer, Lung Cancer
Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients
To investigate the effect of percutaneous electrical stimulation on chemotherapy-induced bone marrow suppression in patients with lung cancer.
- Trial name
- NCT02663492
- Testing
- TEAS, Sanguisorba officinalis L.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji University
Malignant Glioma, Myelosuppression
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
This research trial studies an adherence monitoring system in managing myelosuppression in patients with newly diagnosed malignant gliomas who are receiving temozolomide and radiation therapy.
- Trial name
- NCT02375334
- Testing
- Medical Chart Review
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer, Small-cell Lung Cancer
Study of Trilaciclib and Lurbinectidin
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer.
- Trial name
- NCT05578326
- Testing
- Trilaciclib, Lurbinectedin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myelosuppression
Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity
We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer.
- Trial name
- NCT05442177
- Testing
- Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment
- Volunteers
- 35 people
- Sponsor
- Taichung Tzu Chi Hospital
Multiple Myeloma
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
The purpose of this study is to see whether combination of low dose lenalidomide(10mg)+ dexamethasone is equally effective in treating relapsed/refractory myeloma in the group of elderly patients and other patients at risk of…
- Trial name
- NCT00482261
- Testing
- Lenalidomide, dexamethasone, aspirin
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Neoplasm Metastasis, Neoplasm Recurrence
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
The objectives of this Phase I/II study are: 1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II. 2.
- Trial name
- NCT01696565
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PhytoHealth Corporation
Lupus Erythematosus, Systemic, Adverse Effects
Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
The purpose of this study is to investigate the relationship between the side effects of cyclophosphamide in the treatment of systemic lupus erythematosus (SLE) in Han Chinese and the genetic polymorphisms of drug metabolizing…
- Trial name
- NCT01060410
- Testing
- Polymorphism Analysis, Cyclophosphamide, Pharmacokinetic analysis
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms, Salivary Gland Diseases
A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
RATIONALE Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. Radiotherapy may cause adverse effect such as xerostomia and mucositis.
- Conditions
- Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases, Mucositis
- Trial name
- NCT01762514
- Testing
- Amifostine every-other-day regimen, Amifostine everyday regimen
- Where
- 7 sites in China
- Volunteers
- 360 people
- Sponsor
- Sun Yat-sen University
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
Ovary Cancer
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
To evaluate the remission effect and safety of intravenous injection of METR-NK cells as adjuvant therapy on bone marrow suppression in patients with ovarian cancer after chemotherapy
- Trial name
- NCT07096583
- Testing
- METR-NK cell（metabolic remodeling nature killer cells）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital
Myelosuppression
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
- Trial name
- NCT06641934
- Testing
- No intervention; Observational study
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Non-small Cell Lung Cancer
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40…
- Trial name
- NCT06370416
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Hematologic Disorder
Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy
The goal of this clinical trial is to learn if Naderin works to prevent low white blood cell counts in people with breast cancer receiving first-line chemotherapy. The main questions it aims to answer are: 1.
- Conditions
- Breast Cancer, Hematologic Disorder, Leukopenia, Chemotherapy-Induced Myelosuppression
- Trial name
- NADERIN-BC (NCT07671547)
- Testing
- Naderin, AC Chemotherapy
- Volunteers
- 79 people
- Sponsor
- MIPO Clinic
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Myelosuppression, Lactic Acidosis
Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions
Linezolid is the second line agent in the treatment of MRSA and PRSP infections, and it is also the drug of choice for VRE infections.
- Conditions
- Myelosuppression, Lactic Acidosis, Peripheral Neuropathy
- Trial name
- NCT03126890
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Bone Marrow Suppression
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .
The clinical study aims to evaluate the safety and efficacy of umbilical cord blood transfusion in treating bone marrow suppression after chemotherapy in elderly patients with MDS and AML
- Trial name
- NCT07201233
- Testing
- Umbilical cord blood
- Volunteers
- 30 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.